%0 Journal Article
%T Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
%A Hiromi Kataoka
%A Hironobu Tsukamoto
%A Makoto Sasaki
%A Naomi Sugimura
%A Satoshi Tanida
%A Takahito Katano
%A Takashi Mizushima
%A Taketo Suzuki
%A Tomonori Yamada
%A Tomoya Sugiyama
%A Tsutomu Mizoshita
%A Yoshihide Kimura
%A Yoshikazu Hirata
%A Yuka Suzuki
%J Archive of "Case Reports in Gastroenterology".
%D 2019
%R 10.1159/000496453
%X Adalimumab dose escalation is one of the most important options in refractory Crohn's disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn's disease patients with loss of response to adalimumab, since there are few reports of adalimumab dose escalation, especially in East Asia
%K Crohn's disease
%K Adalimumab dose escalation
%K Loss of response
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547276/